Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.62 |
| ▸ | MMP12 | P39900 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276819 | 0.96 | PRKCA (0.58) | PRKCAMMP12L3MBTL1NR1I2CYP3A4 | |
| SCHEMBL2278834 | 0.94 | PRKCA (0.55) | PRKCAMMP12L3MBTL1NR1I2CYP3A4 | |
| SCHEMBL4212003 | 0.93 | PRKCA (0.65) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL2278835 | 0.92 | PRKCA (0.52) | PRKCAMMP12L3MBTL1NR1I2CYP3A4 | |
| SCHEMBL4208318 | 0.91 | PRKCA (0.62) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL3682090 | 0.87 | PRKCA (0.59) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL2277012 | 0.86 | PRKCA (0.56) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL4208637 | 0.86 | PRKCA (0.65) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL4211262 | 0.85 | PRKCA (0.64) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL2277965 | 0.85 | PRKCA (0.54) | PRKCAMMP12NR1I2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785425-B2 | 11β-hydroxyandrosta-4-ene-3-ones | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. | 2014-07-22 | — | — | US | disclosed |
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMA ADVANCE RESEARCH COMPANY (IN) | 2009-02-26 | — | — | US | disclosed |
| US-20090048239-A1 | Therapeutic compounds | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048239-A1 | Therapeutic compounds | RRP1B, RCE1, CTSZ | PRKCA 4250/4885MMP12 2067/4885L3MBTL1 1024/4885 |
| US-20090054388-A1 | NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES | HSD11B1, HSD3B1, HSD3B2 | PRKCA 1840/4885MMP12 587/4885L3MBTL1 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.